Merck KGaA, with hold still clouding prospects, guides MS drug past durability test ahead of phase 3 data

Merck KGaA is back with another update on the durability of its BTK inhibitor evobrutinib, sharing data that shows the effect on relapse rates lasts for at least five years. But with the program on partial clinical hold and phase 3 data imminent, the update may soon be overshadowed by other developments.